Results 201 to 210 of about 14,230,992 (393)
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong +6 more
wiley +1 more source
Sustained Transcriptional Response to Lipopolysaccharide and Interleukin-4 in an Immortalized Mouse Microglial Cell Line. [PDF]
Herrero-González A +6 more
europepmc +1 more source
We report a new thiolate‐reactive α,α‐gem‐dibromo lactam warhead that activates transcription factor Nrf2 and demonstrates anti‐inflammatory activities, which have implications in cancer, neurodegeneration, and cardiovascular diseases. RNA‐seq illuminated detailed transcriptional profiles, and chemical reactions with cysteine‐containing compounds ...
Beau R. Brummel +16 more
wiley +1 more source
Contents of interleukins-4 and 6 in the serum of blood of children with bronchial asthma, dependence on the severity and level of the control of the diseases [PDF]
V.М. Dudnyk, O.V. Kutsak
openalex +1 more source
Study on the correlation between Interleukin 4 and febrile seizures. [PDF]
Xiang X +7 more
europepmc +1 more source
SETDB1 is progressively downregulated in ALD, correlating with disease severity. SETDB1 deficiency impairs LAP by disrupting Rubicon membrane localization, leading to defective lipid droplet clearance. Concurrently, loss of SETDB1 reduces nuclear LC3B, causing R‐loop accumulation and cGAS‐STING‐driven inflammation. Lipidated LC3B mediates LAP‐dependent
Yi Zhang +17 more
wiley +1 more source
Disentangling depression in women with diabetes: evidence for measure-dependent associations with interleukin-4 and common inflammatory biomarkers. [PDF]
Perez NB +9 more
europepmc +1 more source
Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann +15 more
wiley +1 more source

